SNX 5422

Drug Profile

SNX 5422

Alternative Names: 113; PF-04929113; PF-113; PF-4929113; SNX-5422

Latest Information Update: 17 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Serenex
  • Developer Esanex; Serenex
  • Class Amides; Antineoplastics; Indazoles; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer
  • Phase I Chronic lymphocytic leukaemia; Haematological malignancies; Lung cancer; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Apr 2018 Pharmacodynamics data from a preclinical study in Chronic lymphocytic leukaemia presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 05 Apr 2018 Development is ongoing in Neuroendocrine-tumours (Combination therapy), Solid tumours, Haematological-malignancies (Refractory metastatic disease), Non-Hodgkin's lymphoma, Lung cancer (Late-stage disease, Second-line therapy or greater) (PO) (Esanex website; 9237210)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top